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Abstract. We explored spatial variation in the prevalence of established molecular markers of antimalarial resistance
across a geographically diverse, highland region ofwesternUganda.We identifiedPlasmodium falciparumCQ resistance
transporter 76Tmutations in all pools, but therewasno evidenceof spatial differences across village-based strata defined
by either altitude or river valley. In contrast, we identified a significant inverse association between altitude and the
prevalence of Plasmodium falciparum multidrug resistance 1 mutations with the largest proportion of Y184F mutations
observed in the low-elevation, high-transmission villages. These results demonstrate the substantial heterogeneity in
resistancemarkers observed across geographic settings, even at relatively small scales, but highlight the complex nature
of these ecological relationships.
The emergence and spread of drug resistance are major
threats to global public health with the most severe conse-
quences residing in sub-Saharan Africa, where the burden of
Plasmodium falciparum malaria is greatest.1,2 Although arte-
misinin combination therapies (ACTs) remain effective, on-
going surveillance is required to identify and contain the
emergenceof resistant parasites.3 The level of drug resistance
in a given area canbe inferred by the studyof knownmolecular
markers, which may provide an early warning of decreasing
efficacy.4
In Uganda, like most of sub-Saharan Africa, chloroquine
(CQ) was the mainstay of treatment for uncomplicated
malaria. High rates of treatment failure, accompanied by the
near universal prevalence of established CQ resistance
mutations led to the adoption of CQ plus sulfadoxine–
pyrimethamine (SP) as first-line therapy in June 2000.5 The
efficacy of CQ–SP combination therapy was short-lived,
resulting in a change to artemether–lumefantrine (AL) in June
2004, although the policy launch did not take place for an-
other 2 years.6
With thewithdrawal of CQ from routine use, reduction in the
prevalence of the P. falciparum CQ resistance transporter
(pfcrt) 76T mutation has been reported in Uganda, consistent
with the trends observed in landmark studies from Malawi.7,8
Re-emergence of CQ-sensitive alleles depends greatly on the
duration of time following the removal of selection pressure
and local factors, such as transmission intensity.9 Therefore,
we sought to examine spatial variation in the prevalence of
established molecular markers of antimalarial resistance
across a geographically diverse, highland region of western
Uganda.
The study area, located in Bugoye subcounty of the Kasese
District, experiences year-roundmalaria transmissionmarked
by semiannual transmission peaks typically following the end
of the rainy seasons. The geography of the subcounty is highly
varied. The westernmost villages, which border the Rwenzori
Mountains National Park, are characterized by steep hillsides
with elevations up to 2,000 m, whereas villages located to the
east are defined by low-lying, level terrain (Figure 1A). As we
have previously demonstrated, this altitudinal gradient results
in heterogenous malaria transmission intensity over a rela-
tively small geographic area.10 The subcounty is also defined
by three river valleys that flow from west to east converging in
the low-lying areas near the health center. Artemether–
lumefantrine was introduced to the area in 2008, but the
supply available at public health facilities did not stabilize until
2011.
We collected malaria rapid diagnostic test (RDT) samples
from theBugoyeLevel III HealthCenter fromMay toNovember
2015 as part of a prospective cohort study of individuals
presenting with undifferentiated fever.11 DNA was extracted
from each RDT sample using the Chelex method, as pre-
viously described.10 Extracted P. falciparum DNA from 219
RDT-positive samples was pooled in an isovolumetric man-
ner, stratified by the river valley and elevation of the individu-
al’s village of residence. The nine resulting pools (Figure 1B)
then underwent PCR amplification targeting specific regions
associated with putative drug resistance, including 1) pfcrt, 2)
Kelch protein K13 (Kelch), and 3) P. falciparum multidrug
resistance (pfmdr1) genes. The PCR conditions and the
analyzed genomic regions are summarized in Supplemental
Table 1. Amplicons were prepared for sequencing using the
KAPA Hyper Prep Kit (Roche Sequencing, Pleasanton, CA)
and were sequenced on MiSeq 300-base pair paired-end
chemistry with a Phi-X spike to increase diversity (Illumina,
San Diego, CA). The raw data can be downloaded from se-
quence read archive (PRJNA555552). All sequence analysis
scriptsneeded to recreatehaplotypesare available fromGitHub
(nickbrazeau/RDTSM_DrugRes_ManuscriptAnalyses).
Sequences were demultiplexed and trimmed using the ex-
tractor module in SeekDeep (Version 2.6.0) with the paired-
end feature allowing for one barcode error and shortened
barcodes.12 Default options were used for the cluster module,
which performs initial clustering and removes chimeric
haplotypes. Final haplotypes were determined with process
cluster for haplotypes with a minimum frequency of 5%.
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Sample pools were processed with a single PCR, which
warranted the higher, more conservative haplotype fre-
quency cutoff. The resulting haplotypes were then evaluated
for putative drug resistance mutations and amino acid
changes using custom R scripts (R Project, Version 3.5.1,
www.r-project.org).
We evaluated the effect of altitude and river valley on the
frequencyof theputativedrug resistancephenotypes (i.e., 74I/
75E/76T and N86/184F for pfcrt and pfmdr1-early, re-
spectively) using simple linear regression weighted by the
number of samples in each pool. Elevation and location were
modeled as disjoint indicator variables based on the cate-
gories described in Figure 1. Models were fit a priori, and
covariates were pruned using backward selection with an al-
pha value of 0.05.
Ethical approval of the study was provided by the in-
stitutional review boards of the Mbarara University of Science
and Technology, the University of North Carolina at Chapel
Hill, and the Uganda National Council for Science and Tech-
nology. Written informed consent was obtained from all the
adult study participants and the caregivers of children.
Sequencing of pfcrt showed the presence of resistant 76T
haplotypes in all pools. The fraction of mutant haplotypes
ranged from16.8% to91.3%, although six of nine of pools had
fractions between 40%and 65% (Figure 2). Overall, there was
no trend between elevation or river valley and the frequency of
pfcrtmutations.
In the early pfmdr1 PCR fragment, the Y184F mutation,
which is associated with amodiaquine exposure, was identi-
fied in all pools except for the one high-elevation pool that
comprised only three clinical samples (Pool 1). In contrast to
the pfcrt analysis, there was evidence for a trend between the
fraction of pfmdr1 mutations and elevation. The largest frac-
tion of Y184 mutations was observed in the three low-
elevation pools (pools 3, 6, and 9), whereas the smallest
fraction was found in two of the three highest elevation
pools (pools 1 and 7). The association was robust in the
linear regressionmodel with the fraction of N86/184F alleles
being lower in both the medium (β = ‒33.04%, ‒65.59% to
‒0.49%, P = 0.05) and high (β = ‒29.85, ‒70.04% to 10.34%,
P = 0.11) elevation pools compared with the low-elevation
pools. No trends were seen in regard to the river valley of
residence.
No mutations were observed in the pfmdr1 N86Y poly-
morphism, which is more consistently associated with the
degree of lumefantrine susceptibility than the Y184F poly-
morphism. Similarly, no resistance mutations were identified
in the Kelch propeller domain in any of the nine pools
(Supplemental Table 2).
Overall, the results of our study provide further insight into
the microepidemiological patterns of antimalarial drug re-
sistance. Most notably, we observed a significant, inverse
correlation between altitude and the frequency of pfmdr1
Y184 mutations. The ecological factors underlying this
finding are, however, complex. For example, although ele-
vation can be a surrogate measure of transmission intensity,
it may also be a proxy for access to care, with the higher
elevation villages to the west of the subcounty being farther
from public health facilities. Residents of these lower trans-
mission villages are likely to have less acquired immunity,
be exposed to increasing clonal infections, and develop
symptoms thatwill promptcare-seekingand treatment—factors
that some models have suggested may contribute to the
rapid spread of resistance in lower transmission set-
tings.13 Yet without access to public facilities, residents
are likely to seek care in the private sector where first-line
ACTs such as AL are less available.14 Unfortunately, our
study is not designed to disentangle these factors, and
FIGURE 1. (A) Topographic map of study area showing the rapid change in altitude and major river valleys. Contour lines demarcate elevation
changes of 200 m. (B) Table of sample pools stratified by elevation and river valley, which can be roughly overlaid on map to left, showing number
of samples and median and interquartile range of parasitemia. This figure appears in color at www.ajtmh.org.
further investigation will be required. At a minimum, these re-
sults suggest that there are not clear associations between
altitude of residence and the prevalence of drug resistance
polymorphisms.
Our finding that approximately half of alleles in each pool
were wild-type pfcrt is consistent with the well-established
phenomenon of wild-type re-emergence following the with-
drawal of CQ as first-line therapy. We do not have historical
data from the site to assess the rate of wild-type pfcrt re-
emergence, but our estimates are similar to those from con-
temporaneous studies fromother areas of Uganda.15 The lack
of an association between the frequency of pfcrt mutations
and elevation may be due to the fact that alleles associated
with drug resistance saturated the country at the time of the
antimalarial policy change.
Our study has a number of strengths, including the unique
geographic setting and use of a validated, high-throughput
pooling technique. To our knowledge, this is the first study to
examine differences in the frequency of putative drug re-
sistance mutations over such a small, yet geographically di-
verse area. Our study also has limitations. First, our samples
were collected from a single clinical site. This approach re-
stricted the number of samples from the more distant, higher
elevation villages. This sampling limitation also could have
created a selection bias with patients from distant villages
presenting with more severe disease. Second, the pools were
not performed in replicate,which could impact the accuracy of
our frequency estimations. We attempted to account for this
limitation by using a very conservative minimum cutoff of 5%
to determine the final haplotypes.
In conclusion, by pooling samples from a geographically
diverse area, we were able to identify an association between
altitude, which often serves as a surrogate marker of trans-
mission intensity, and the frequency of the Y184F mutation,
but this association was not seen across multiple drug
resistance–conferring alleles, suggesting that the relationship
involves factors other than transmission intensity.
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